Changes of Cerebrospinal Fluid Peptides due to Tauopathy
- 27 April 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 58 (2) , 507-520
Abstract
Alzheimer’s disease (AD) and progressive supranuclear palsy are two common neurodegenerative tauopathies, and the most common cause of progressive brain dementia in elderly affecting more than 35 million people. The tauopathies are characterized by abnormal deposition of microtubule associated protein tau into intracellular neurofibrillary tangles composed mainly of the hyperphosphorylated form of the protein. The diagnosis of tauopathies is based on the presence of clinical features and pathological changes. Over the last decade, there has been an intensive search for novel biochemical markers for clinical diagnosis of AD and other tauopathies. In the present study, we used transgenic rat model for tauopathy expressing human truncated tau protein (aa 151–391/4R) to analyze the cerebrospinal fluid (CSF) peptidome using liquid chromatography – matrix assisted laser desorption/ionization mass spectrometry (LC-MALDI TOF/TOF). From 345 peptides, we identified a total of 175 proteins. Among them, 17 proteins were significantly altered in the CSF of transgenic rats. The following proteins were elevated in the CSF of transgenic rats when compared to the control animals: neurofilament light and medium chain, apolipoprotein E, gamma-synuclein, chromogranin A, reticulon-4, secretogranin-2, calsyntein-1 and -3, endothelin-3, neuroendocrine protein B72A, alpha-1-macroglobulin, and augurin. Interestingly most of the identified proteins were previously linked to AD and other tauopathies, indicating the significance of transgenic animals in biomarker validation.Keywords
This publication has 66 references indexed in Scilit:
- The role of urinary peptidomics in kidney disease researchKidney International, 2016
- Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assayMolecular Neurodegeneration, 2015
- Current peptidomics: Applications, purification, identification, quantification, and functional analysisProteomics, 2014
- Data in support of peptidomic analysis of spermatozoa during epididymal maturationData in Brief, 2014
- Peptidomics of Urine and Other Biofluids for Cancer DiagnosticsClinical Chemistry, 2014
- Historical perspective of peptidomicsEuPA Open Proteomics, 2014
- Deconvoluting the ‘omics’ for organ transplantationCurrent Opinion in Organ Transplantation, 2009
- The Role of Proteomics in Clinical Cardiovascular Biomarker DiscoveryMolecular & Cellular Proteomics, 2008
- The Process Chain for Peptidomic Biomarker DiscoveryDisease Markers, 2006
- The potential of proteomics and peptidomics for allergy and asthma researchAllergy, 2005